Genetically engineered T cells are powerful new medicines, offering hope for curative responses in patients with cancer. Chimeric antigen receptor (CAR) T cells were recently approved by the US Food and Drug Administration and are poised to enter the practice of medicine for leukemia and lymphoma, demonstrating that engineered immune cells can serve as a powerful new class of cancer therapeutics. The emergence of synthetic biology approaches for cellular engineering provides a broadly expanded set of tools for programming immune cells for enhanced function. Advances in T cell engineering, genetic editing, the selection of optimal lymphocytes, and cell manufacturing have the potential to broaden T cell-based therapies and foster new applications beyond oncology, in infectious diseases, organ transplantation, and autoimmunity.

中文翻译：

---

新兴的癌症细胞疗法。

基因工程T细胞是功能强大的新药，为癌症患者的治愈反应提供了希望。嵌合抗原受体（CAR）T细胞最近已获得美国食品和药物管理局（FDA）的批准，并有望进入白血病和淋巴瘤的医学实践，证明工程改造的免疫细胞可以作为一种强大的新型癌症治疗方法。用于细胞工程的合成生物学方法的出现为编程免疫细胞以增强功能提供了广泛扩展的工具集。T细胞工程，基因编辑，最佳淋巴细胞的选择和细胞制造方面的进展，有可能拓宽基于T细胞的疗法，并在肿瘤学，感染性疾病，器官移植和自身免疫等领域推广新的应用。